Table 1 IMP3 related to clinico-pathological parameters of prostate cancer
Variable | Patients (n) | Number of patients (IMP-Expression) (%) | p-Value (linear by linear) | |||
|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | |||
pT-status | 0.5 | |||||
pT2 | 213 | 46 (21.6%) | 131 (61.5%) | 34 (16%) | 2 (0.9%) | |
pT3&4 | 212 | 25 (11.8%) | 163 (76.9%) | 23 (10.8%) | 1 (0.5%) | |
Gleason score | 0.048 | |||||
5-6 | 129 | 29 (22.5%) | 85 (65.9%) | 14 (10.9%) | 1 (0.8%) | |
7 | 182 | 28 (15.4%) | 127 (69.8%) | 26 (14.3%) | 1 (0.5%) | |
8-9 | 114 | 14 (12.3%) | 82 (71.9%) | 17 (14.9%) | 1 (0.9%) | |
Margin status | 0.115 | |||||
R0 | 262 | 54 (20.6%) | 171 (65.3%) | 34 (13%) | 3 (1.1%) | |
R1 | 163 | 17 (10.4%) | 123 (75.5%) | 23 (14.1%) | 0 (0%) | |
PSA (pre-OP) | 0.21 | |||||
< 10 ng/ml | 192 | 37 (19.3%) | 130 (67.7%) | 24 (12.5%) | 1 (0.5%) | |
≥10 ng/ml | 233 | 34 (14.6%) | 164 (70.4%) | 33 (14.2%) | 2 (0.9%) | |
Age | 0.693 | |||||
≤64 y | 230 | 33 (14.3%) | 168 (73%) | 27 (11.7%) | 2 (0.9%) | |
> 64 y | 195 | 38 (19.5%) | 126 (64.6%) | 30 (15.4%) | 1 (0.5%) |